123 122

Cited 0 times in

Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer.

 Changhoon Yoo  ;  Sung-Bae Kim  ;  Jungsil Ro  ;  Seock-Ah Im  ;  Young-Hyuck Im  ;  Jee Hyun Kim  ;  Jin-Hee Ahn  ;  Kyung Hae Jung  ;  Hong Suk Song  ;  Seok Yun Kang  ;  Hee Sook Park  ;  Hyun-Cheol Chung 
 CANCER RESEARCH AND TREATMENT, Vol.48(2) : 499-507, 2016 
Journal Title
Issue Date
Adult ; Aged ; Angiogenesis Inhibitors/administration & dosage ; Angiogenesis Inhibitors/pharmacology* ; Angiogenesis Inhibitors/therapeutic use* ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; Biomarkers, Tumor/blood* ; Breast Neoplasms/blood* ; Breast Neoplasms/drug therapy* ; Breast Neoplasms/pathology ; C-Reactive Protein/analysis ; Enzyme-Linked Immunosorbent Assay ; Female ; Fibroblast Growth Factors/blood ; Humans ; Indoles/administration & dosage ; Indoles/pharmacology* ; Indoles/therapeutic use* ; Interleukin-6/blood ; Middle Aged ; Neoplasm Metastasis/drug therapy* ; Propionates/administration & dosage ; Propionates/pharmacology* ; Propionates/therapeutic use* ; Taxoids/administration & dosage ; Taxoids/pharmacology ; Taxoids/therapeutic use ; Vascular Endothelial Growth Factor A/blood
Angiogenesis ; Biological markers ; Breast neoplasms ; Pharmacology ; TSU-68
PURPOSE: This study analyzed the role of plasma biomarkers for TSU-68 in a previous phase II trial comparing TSU-68 plus docetaxel and docetaxel alone in patients with metastatic breast cancer. MATERIALS AND METHODS: A total of 77 patients were eligible for this study (38 in the TSU-68 plus docetaxel arm and 39 in the docetaxel alone arm). Blood samples were collected prior to the start of each cycle, and vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF)-AA, -AB, -BB, fibroblast growth factor, M30, C-reactive protein (CRP), and interleukin 6 (IL-6) levels were measured using enzyme linked immunosorbent assay. The primary endpoint was progression-free survival (PFS). RESULTS: In patients with baseline PDGF-AA ≥ median, median PFS was significantly worse in the TSU-68 plus docetaxel group than in the docetaxel alone group (5.4 months vs. 13.7 months, p=0.049), while a trend toward a PFS benefit was observed in those with baseline PDGF-AA < median (9.7 months vs. 4.0 months, p=0.18; p for interaction=0.03). In the TSU-68 plus docetaxel group, PFS showed significant association with fold changes in CRP (p=0.001), IL-6 (p < .001), PDGF-BB (p=0.02), and VEGF (p=0.047) following the first treatment cycle. CONCLUSION: Baseline PDGF-AA levels and dynamics of VEGF, PDGF-BB, CRP, and IL-6 levels were predictive for the efficacy of TSU-68.
Files in This Item:
T201602074.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Chung, Hyun Cheol(정현철) ORCID logo https://orcid.org/0000-0002-0920-9471
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.